Cargando…

Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography

INTRODUCTION: Group comparisons demonstrate greater visuospatial and memory deficits and temporoparietal-predominant degeneration on neuroimaging in patients with corticobasal syndrome (CBS) found to have Alzheimer’s disease (AD) pathology versus those with underlying frontotemporal lobar degenerati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sha, Sharon J, Ghosh, Pia M, Lee, Suzee E, Corbetta-Rastelli, Chiara, Jagust, Willian J, Kornak, John, Rankin, Katherine P, Grinberg, Lea T, Vinters, Harry V, Mendez, Mario F, Dickson, Dennis W, Seeley, William W, Gorno-Tempini, Marilu, Kramer, Joel, Miller, Bruce L, Boxer, Adam L, Rabinovici, Gil D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346122/
https://www.ncbi.nlm.nih.gov/pubmed/25733984
http://dx.doi.org/10.1186/s13195-014-0093-y
_version_ 1782359689066971136
author Sha, Sharon J
Ghosh, Pia M
Lee, Suzee E
Corbetta-Rastelli, Chiara
Jagust, Willian J
Kornak, John
Rankin, Katherine P
Grinberg, Lea T
Vinters, Harry V
Mendez, Mario F
Dickson, Dennis W
Seeley, William W
Gorno-Tempini, Marilu
Kramer, Joel
Miller, Bruce L
Boxer, Adam L
Rabinovici, Gil D
author_facet Sha, Sharon J
Ghosh, Pia M
Lee, Suzee E
Corbetta-Rastelli, Chiara
Jagust, Willian J
Kornak, John
Rankin, Katherine P
Grinberg, Lea T
Vinters, Harry V
Mendez, Mario F
Dickson, Dennis W
Seeley, William W
Gorno-Tempini, Marilu
Kramer, Joel
Miller, Bruce L
Boxer, Adam L
Rabinovici, Gil D
author_sort Sha, Sharon J
collection PubMed
description INTRODUCTION: Group comparisons demonstrate greater visuospatial and memory deficits and temporoparietal-predominant degeneration on neuroimaging in patients with corticobasal syndrome (CBS) found to have Alzheimer’s disease (AD) pathology versus those with underlying frontotemporal lobar degeneration (FTLD). The value of these features in predicting underlying AD pathology in individual patients is unknown. The goal of this study is to evaluate the utility of modified clinical criteria and visual interpretations of magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) for predicting amyloid deposition (as a surrogate of Alzheimer’s disease neuropathology) in patients presenting with CBS. METHODS: In total, 25 patients meeting CBS core criteria underwent amyloid (Pittsburgh compound B; PIB) PET scans. Clinical records, MRI, and FDG scans were reviewed blinded to PIB results. Modified clinical criteria were used to classify CBS patients as temporoparietal variant CBS (tpvCBS) or frontal variant CBS (fvCBS). MRI and FDG-PET were classified based on the predominant atrophy/hypometabolism pattern (frontal or temporoparietal). RESULTS: A total of 9 out of 13 patients classified as tpvCBS were PIB+, compared to 2out of 12 patients classified as fvCBS (P < 0.01, sensitivity 82%, specificity 71% for PIB+ status). Visual MRI reads had 73% sensitivity and 46% specificity for PIB+ status with moderate intra-rater reliability (Cohen’s kappa = 0.42). Visual FDG reads had higher sensitivity (91%) for PIB+ status with perfect intra-rater reliability (kappa = 1.00), though specificity was low (50%). PIB results were confirmed in all 8 patients with available histopathology (3 PIB+ with confirmed AD, 5 PIB- with FTLD). CONCLUSIONS: Splitting CBS patients into frontal or temporoparietal clinical variants can help predict the likelihood of underlying AD, but criteria require further refinement. Temporoparietal-predominant neuroimaging patterns are sensitive but not specific for AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-014-0093-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4346122
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43461222015-03-03 Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography Sha, Sharon J Ghosh, Pia M Lee, Suzee E Corbetta-Rastelli, Chiara Jagust, Willian J Kornak, John Rankin, Katherine P Grinberg, Lea T Vinters, Harry V Mendez, Mario F Dickson, Dennis W Seeley, William W Gorno-Tempini, Marilu Kramer, Joel Miller, Bruce L Boxer, Adam L Rabinovici, Gil D Alzheimers Res Ther Research INTRODUCTION: Group comparisons demonstrate greater visuospatial and memory deficits and temporoparietal-predominant degeneration on neuroimaging in patients with corticobasal syndrome (CBS) found to have Alzheimer’s disease (AD) pathology versus those with underlying frontotemporal lobar degeneration (FTLD). The value of these features in predicting underlying AD pathology in individual patients is unknown. The goal of this study is to evaluate the utility of modified clinical criteria and visual interpretations of magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) for predicting amyloid deposition (as a surrogate of Alzheimer’s disease neuropathology) in patients presenting with CBS. METHODS: In total, 25 patients meeting CBS core criteria underwent amyloid (Pittsburgh compound B; PIB) PET scans. Clinical records, MRI, and FDG scans were reviewed blinded to PIB results. Modified clinical criteria were used to classify CBS patients as temporoparietal variant CBS (tpvCBS) or frontal variant CBS (fvCBS). MRI and FDG-PET were classified based on the predominant atrophy/hypometabolism pattern (frontal or temporoparietal). RESULTS: A total of 9 out of 13 patients classified as tpvCBS were PIB+, compared to 2out of 12 patients classified as fvCBS (P < 0.01, sensitivity 82%, specificity 71% for PIB+ status). Visual MRI reads had 73% sensitivity and 46% specificity for PIB+ status with moderate intra-rater reliability (Cohen’s kappa = 0.42). Visual FDG reads had higher sensitivity (91%) for PIB+ status with perfect intra-rater reliability (kappa = 1.00), though specificity was low (50%). PIB results were confirmed in all 8 patients with available histopathology (3 PIB+ with confirmed AD, 5 PIB- with FTLD). CONCLUSIONS: Splitting CBS patients into frontal or temporoparietal clinical variants can help predict the likelihood of underlying AD, but criteria require further refinement. Temporoparietal-predominant neuroimaging patterns are sensitive but not specific for AD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13195-014-0093-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-02 /pmc/articles/PMC4346122/ /pubmed/25733984 http://dx.doi.org/10.1186/s13195-014-0093-y Text en © Sha et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Sha, Sharon J
Ghosh, Pia M
Lee, Suzee E
Corbetta-Rastelli, Chiara
Jagust, Willian J
Kornak, John
Rankin, Katherine P
Grinberg, Lea T
Vinters, Harry V
Mendez, Mario F
Dickson, Dennis W
Seeley, William W
Gorno-Tempini, Marilu
Kramer, Joel
Miller, Bruce L
Boxer, Adam L
Rabinovici, Gil D
Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography
title Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography
title_full Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography
title_fullStr Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography
title_full_unstemmed Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography
title_short Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography
title_sort predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346122/
https://www.ncbi.nlm.nih.gov/pubmed/25733984
http://dx.doi.org/10.1186/s13195-014-0093-y
work_keys_str_mv AT shasharonj predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT ghoshpiam predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT leesuzeee predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT corbettarastellichiara predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT jagustwillianj predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT kornakjohn predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT rankinkatherinep predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT grinbergleat predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT vintersharryv predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT mendezmariof predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT dicksondennisw predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT seeleywilliamw predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT gornotempinimarilu predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT kramerjoel predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT millerbrucel predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT boxeradaml predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography
AT rabinovicigild predictingamyloidstatusincorticobasalsyndromeusingmodifiedclinicalcriteriamagneticresonanceimagingandfluorodeoxyglucosepositronemissiontomography